The report “Drug Screening Market by Product ((Immunoassay Analyzer, Chromatography, Breathalyzer, Rapid Test Device, Assay Kits)), Drug Screening Services, Sample Type (Urine, Hair, Oral), End User (Workplace, Criminal Justice, Hospital) – Global Forecast to 2022″, The drug screening market is expected to reach USD 8.63 Billion by 2022 from USD 5.32 Billion in 2017, at a CAGR of 10.2%. This high growth rate is attributed to factors such as growing drug and alcohol consumption; government funding in major markets, enforcement of stringent laws mandating drug and alcohol testing, and regulatory approvals and new product and service launches.
Get 10% customization on reports:
Factors such as growing drug & alcohol consumption, enforcement of stringent laws mandating drug and alcohol testing, and regulatory approvals and new product & service launches are driving the growth of the market.
Browse and in-depth TOC on “Drug Screening Market”
204 – Tables
42 – Figures
203 – Pages
Breathalyzers are expected to dominate the drug screening products market in 2017.
Based on product, the drug screening market is segmented into analytical instruments, rapid testing devices, and consumables. In 2017, the breathalyzers segment is expected to dominate the market. Growing alcohol consumption and drunken driving cases, stringent government laws mandating drug and alcohol testing, and technological advancements in this market are some of the key factors driving the growth of the breathalyzers market.
Based on sample type, the oral fluid segment is projected to grow at the highest CAGR during the forecast period.
By sample type, drug screening market is segmented into urine, breath, oral fluid, hair, and other samples. Among these the oral fluid segment is expected to register the highest CAGR during the forecast period. The high growth of this segment is attributed to the increasing preference for oral fluid samples because of the convenient collection method, no specific requirement for sample collection, and low risk of sample adulteration.
Speak to Analyst @